Table of Contents
Increasing Applications of Biomarkers are Driving Growth
Biomarkers will certainly change the way healthcare is provided. They are being increasingly used in early drug development and for clinical use as well, boosting their demand. The penetration of biomarkers in various therapeutic applications, the impact of market trends and dynamics are analysed in this study. This research service offers market overview, Market Engineering measurements, revenue forecasts, company profiling and key trends for the market and its segments, namely, genomics, proteomics, metabolomics and imaging biomarkers.
-The information contained in this research service was derived from a variety of relevant primary and secondary information sources.
-Primary interviews were conducted with leading tier 1 and tier 2 companies and industry stakeholders, such as key clinicians, the research and development (R&D) community, heads of business development, laboratory personnel and key opinion leaders.
-Secondary data sources include government and public health organisation Websites, the World Health Organization (WHO), the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) publications, annual reports, investor presentations, press releases, government public sources, pharmaceutical industry databases and published articles in scientific and medical journals.
-For the total biomarkers and segments, revenue forecasting is performed using a robust, data-driven approach. Current trends, products, technologies and emerging trends have been taken into account, and aggregate figures are provided.
For Market Engineering research, Frost & Sullivan uses tried and tested marketing techniques to provide structure to the research and an easy format to compare results across different countries and markets over time. This project was carried out using primary (telephone or face-to-face interviews) and secondary (published and online material) research as the principle methods of data gathering. The focus of the interviews for this project was primarily the respondent types outlined below.
-Key regulatory bodies
-Frost & Sullivan published research services
-Decision support databases
-Country industry forecasts
-The Western European biomarkers market in drug discovery and development will continue to grow - from $ million in 2013 to $ million in 2019, at a compound annual growth rate (CAGR) of % from 2013 to 2020.The use of biomarker-based tests in drug discovery, early diagnosis and prognosis is in the growth stage.
-Advancements in multiplexing will lead to the development of biomarker panels with a higher clinical value. The discovery of biomarkers from samples like urine, breath and saliva, as well as the development of noninvasive tests, will find increased application in infectious disease and cancer testing, in which repeat studies are needed to be able monitor the diseases.
-The development of multi-biomarker panels that can be used to provide accurate predictive value is important, and companies are working towards discovering and integrating results from different discovery platforms to build such panels.
-The adoption of genomics- and proteomics-based biomarkers is currently the highest, with a number of novel lipidomics and immunomics markers also coming to the fore.
-Complex diseases with unmet needs are the major potential areas for biomarker development. Traumatic brain injury (TBI), cardiovascular diseases and autoimmune diseases are some of the areas witnessing quality R&D of novel biomarker-based tests.
-Various European Governments and health authorities are focussing on investing their funding in biomarker R&D. Various knowledge networks and consortia have been formed to help this cause. The U.K. Biobank, the Biomarkers Consortium and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) E-Register of Studies are some examples.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...
The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Increasing diagnostic applications of biomarkers, increasing ...
The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...